Fintepla (Fenfluramine) provides clinically meaningful reduction in frequency of seizures resulting in a drop in patients with Lennox-Gastaut Syndrome for up to 1 year: interim analysis of an open-label extension study.
Published in 2021 by
Kate Riney 
